MYOV insider filings

Myovant Sciences Ltd. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-03-10. Screen MYOV transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for MYOV between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Myovant Sciences Ltd.

FiledFormInsiderReported transactionsSource
2023-03-104Valente Nancy — DirectorDisposition to issuer (D): 3,673 · Disposition to issuer (D): 36,892 (derivative)EDGAR
2023-03-104Merendino Lauren — Chief Commercial OfficerDisposition to issuer (D): 21,791 · Disposition to issuer (D): 147,747 · Disposition to issuer (D): 123,300 (derivative) · Disposition to issuer (D): 103,703 (derivative)EDGAR
2023-03-104Mehra Uneek — Principal Financial OfficerDisposition to issuer (D): 20,724 · Disposition to issuer (D): 181,972 · Disposition to issuer (D): 165,192 (derivative) · Disposition to issuer (D): 111,111 (derivative)EDGAR
2023-03-104Lang Matthew — General Counsel & Corp. Secy.Disposition to issuer (D): 113,145 · Disposition to issuer (D): 241,158 · Disposition to issuer (D): 220,000 (derivative) · Disposition to issuer (D): 87,050 (derivative) · Disposition to issuer (D): 152,110 (derivative) · Disposition to issuer (D): 170,396 (derivative) · +2 moreEDGAR
2023-03-104Curran Terrie — DirectorDisposition to issuer (D): 3,673 · Disposition to issuer (D): 33,846 (derivative) · Disposition to issuer (D): 11,154 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 5,250 (derivative) · +2 moreEDGAR
2023-03-104Arjona Ferreira Juan Camilo — Chief Medical OfficerDisposition to issuer (D): 86,602 · Disposition to issuer (D): 160,082 · Disposition to issuer (D): 155,300 (derivative) · Disposition to issuer (D): 63,717 (derivative) · Disposition to issuer (D): 65,863 (derivative) · Disposition to issuer (D): 134,464 (derivative) · +2 moreEDGAR
2023-03-104Gulfo Adele M. — DirectorDisposition to issuer (D): 3,673 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 21,603 (derivative) · Disposition to issuer (D): 21,096 (derivative)EDGAR
2023-03-104Marek David C — Principal Executive Officer, DirectorDisposition to issuer (D): 95,675 · Disposition to issuer (D): 321,924 · Disposition to issuer (D): 306,427 (derivative) · Disposition to issuer (D): 208,218 (derivative) · Disposition to issuer (D): 204,808 (derivative) · Disposition to issuer (D): 134,567 (derivative)EDGAR
2023-03-104GUINAN MARK — DirectorDisposition to issuer (D): 3,673 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 58,608 (derivative) · Disposition to issuer (D): 21,603 (derivative) · Disposition to issuer (D): 21,096 (derivative)EDGAR
2023-03-104Sumitomo Chemical Co., Ltd. — 10% owner
Sumitomo Pharma Co., Ltd. — 10% owner
Sumitovant Biopharma Ltd. — 10% owner
Purchase (P): 51,599,200 @ $27EDGAR
2023-03-104POTTER MYRTLE S — DirectorDisposition to issuer (D): 3,673 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 58,608 (derivative) · Disposition to issuer (D): 21,603 (derivative) · Disposition to issuer (D): 21,096 (derivative)EDGAR
2023-03-064Sumitomo Chemical Co., Ltd. — 10% owner
Sumitomo Pharma Co., Ltd. — 10% owner
Sumitovant Biopharma Ltd. — 10% owner
Other (J): 4,243,005 @ $0 · Other (J): 1 (derivative) @ $0EDGAR
2023-01-204Lang Matthew — General Counsel & Corp. Secy.Sale (S): 1,272 @ $26.89EDGAR
2023-01-204Merendino Lauren — Chief Commercial OfficerSale (S): 2,008 @ $26.89EDGAR
2023-01-204Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 1,109 @ $26.89EDGAR
2023-01-204Marek David C — Principal Executive Officer, DirectorSale (S): 8,037 @ $26.89EDGAR
2023-01-054Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 2,251 @ $26.90EDGAR
2023-01-054Lang Matthew — General Counsel & Corp. Secy.Sale (S): 2,779 @ $26.90EDGAR
2022-12-204Mehra Uneek — Principal Financial OfficerSale (S): 2,241 @ $26.75EDGAR
2022-10-284Curran Terrie — DirectorGrant/award (A): 9,859 @ $0EDGAR
2022-10-284Valente Nancy — DirectorGrant/award (A): 9,859 @ $0EDGAR
2022-10-284Gulfo Adele M. — DirectorGrant/award (A): 9,859 @ $0EDGAR
2022-10-284GUINAN MARK — DirectorGrant/award (A): 9,859 @ $0EDGAR
2022-10-284POTTER MYRTLE S — DirectorGrant/award (A): 9,859 @ $0EDGAR
2022-10-204Merendino Lauren — Chief Commercial OfficerSale (S): 1,703 @ $25.20EDGAR
2022-10-204Lang Matthew — General Counsel & Corp. Secy.Sale (S): 1,933 @ $25.20EDGAR
2022-10-204Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 1,604 @ $25.20EDGAR
2022-10-204Marek David C — Principal Executive Officer, DirectorSale (S): 11,156 @ $25.20EDGAR
2022-10-064Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 2,738 @ $24.40EDGAR
2022-10-064Lang Matthew — General Counsel & Corp. Secy.Sale (S): 3,679 @ $24.40EDGAR
2022-09-204Mehra Uneek — Principal Financial OfficerSale (S): 9,243 @ $18.86EDGAR
2022-08-164Lang Matthew — General Counsel & Corp. Secy.Grant/award (A): 124,780 @ $0 · Sale (S): 31,214 @ $18.23EDGAR
2022-07-204Lang Matthew — General Counsel & Corp. Secy.Sale (S): 1,935 @ $12.87EDGAR
2022-07-204Merendino Lauren — Chief Commercial OfficerSale (S): 1,704 @ $12.87EDGAR
2022-07-204Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 1,606 @ $12.87EDGAR
2022-07-204Marek David C — Principal Executive Officer, DirectorSale (S): 11,164 @ $12.87EDGAR
2022-07-084Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 2,755 @ $13.40EDGAR
2022-07-084Lang Matthew — General Counsel & Corp. Secy.Sale (S): 3,702 @ $13.40EDGAR
2022-06-014Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 1,382 @ $10.07EDGAR
2022-04-214Lang Matthew — General Counsel & Corp. Secy.Sale (S): 8,002 @ $10.45EDGAR
2022-04-214Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 4,632 @ $10.45EDGAR
2022-04-214Merendino Lauren — Chief Commercial OfficerSale (S): 7,049 @ $10.45EDGAR
2022-04-214Marek David C — Principal Executive Officer, DirectorSale (S): 24,594 @ $10.45EDGAR
2022-04-194Mehra Uneek — Principal Financial OfficerGrant/award (A): 111,111 @ $0EDGAR
2022-04-194Arjona Ferreira Juan Camilo — Chief Medical OfficerGrant/award (A): 103,703 @ $0EDGAR
2022-04-194Lang Matthew — General Counsel & Corp. Secy.Grant/award (A): 111,111 @ $0EDGAR
2022-04-194Merendino Lauren — Chief Commercial OfficerGrant/award (A): 103,703 @ $0EDGAR
2022-04-194Marek David C — Principal Executive Officer, DirectorGrant/award (A): 134,567 @ $0 · Grant/award (A): 204,808 (derivative) @ $0EDGAR
2022-04-074Lang Matthew — General Counsel & Corp. Secy.Sale (S): 2,436 @ $13.78EDGAR
2022-04-074Arjona Ferreira Juan Camilo — Chief Medical OfficerSale (S): 1,922 @ $13.78EDGAR

Recent 8-K events — Myovant Sciences Ltd.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-03-108-K2.01 — Completion of Acquisition or Disposition of Assets
3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
3.03 — Material Modification to Rights of Security Holders
5.01 — Changes in Control of Registrant
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2023-03-018-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2023-01-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-10-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-10-248-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-10-218-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2022-10-038-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-07-278-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-05-108-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-03-258-K5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=MYOV returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs